Leist Slide 10 We are also affording MRI a significant and essential role in the assessment. I’m look here at FLARE and obviously enhancing lesions with respect to accumulation of new lesions. Not depicted over here is atrophy; at this point in time in clinical care, in individual patients this is the measure that is more difficult to use. Leist Slide 11 How do we measure? Well in the center over here you see no evidence of disease activity, no apparent evidence of disease activity where we are looking at EDSS relapses in MRI activity. We can obviously expand this in order to take advantage of the 25-foot walk into nine-hole peg test to have additional assessments, particularly in patients with disability. And we can restart essentially, assess patients with respect to motoric involvement with respect to activity respectively progression. Leist Slide 12 What these measures do not assess is obviously cognitive function. And we start in clinical trials we are starting to expand and the single digit modality test over here is representative for cognitive measures. We all know that this is one of the measures, but it doesn’t assess all domains that may be important in multiple sclerosis. We also understand the vision and have had a lot of discussions around vision and its importance. Leist Slide 13
Leist Slide 10 We are also affording MRI a significant and essential role in the assessment. I’m look here at FLARE and obviously enhancing lesions with respect to accumulation of new lesions. Not depicted over here is atrophy; at this point in time in clinical care, in individual patients this is the measure that is more difficult to use. Leist Slide 11 How do we measure? Well in the center over here you see no evidence of disease activity, no apparent evidence of disease activity where we are looking at EDSS relapses in MRI activity. We can obviously expand this in order to take advantage of the 25-foot walk into nine-hole peg test to have additional assessments, particularly in patients with disability. And we can restart essentially, assess patients with respect to motoric involvement with respect to activity respectively progression. Leist Slide 12 What these measures do not assess is obviously cognitive function. And we start in clinical trials we are starting to expand and the single digit modality test over here is representative for cognitive measures. We all know that this is one of the measures, but it doesn’t assess all domains that may be important in multiple sclerosis. We also understand the vision and have had a lot of discussions around vision and its importance. Leist Slide 13
2338_01.docx